2023年12月6日 · Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody–drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant...

2024年11月29日 · MIRV is a Food and Drug Administration-approved FRα-targeting antibody–drug conjugate. MIRV was assessed as ≥3L treatment for FRα-positive PSOC in the phase II PICCOLO trial. MIRV was efficacious in ORR …

2024年11月29日 · MIRV as ≥3L treatment in heavily pretreated recurrent FRα-positive PSOC demonstrated notable efficacy and tolerable safety, including among those with prior PD on or within 30 days of PARPi (NCT05041257).

2025年3月18日 · Mirvetuximab soravtansine-gynx (MIRV), an antibody-drug conjugate targeting folate receptor alpha (FRα), has emerged as a promising treatment for platinum-resistant ovarian cancer [].Recent clinical trials have highlighted MIRV’s potential to improve outcomes, particularly in high-grade serous carcinoma (HGSC), a prevalent and aggressive form of OEC.

2024年11月29日 · Background: Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class, folate receptor alpha (FRa)-targeting antibodyedrug conjugate with United States Food and Drug Administration approval for FR -positive platinum-resistant ovarian cancer.

2024年4月1日 · Mirvetuximab soravtansine-gynx (MIRV) is a conjugate of a folate receptor alpha (FRα)-directed antibody and the maytansinoid microtubule inhibitor, DM4. Accumulating pre-clinical and clinical data supported the safety and anti-tumor activity of MIRV in …

2024年7月31日 · MIRV is made up of an antibody that binds to a specific protein (folate receptor alpha [FRα]) on cancer cells to directly deliver a cancer-killing drug. MIRV received US FDA approval to be used as a therapy for patients with ovarian cancer who are resistant to platinum-based chemotherapy and express high levels of FRα.

2025年3月6日 · Mirvetuximab Soravtansine (MIRV), the only approved ADC targeting FRα, comprises a humanized anti-FRα monoclonal antibody (M9346A), a cleavable linker (sulfo-SPDB), and a microtubule inhibitor (DM4). It precisely targets FRα-positive tumor cells, leading to cell cycle arrest and apoptosis via DM4-mediated microtubule disruption [10,11,12 ...

Ocular AEs occurring with MIRV are primarily low grade and mostly resolvable blurred vision, keratopathy, and dry eye. Awareness of MIRV’s safety profile and ocular mitigation steps may improve outcomes by facilitating adherence to treatment.

2025年3月1日 · MIRV is a Food and Drug Administration-approved FRα-targeting antibody–drug conjugate. MIRV was assessed as ≥3L treatment for FRα-positive PSOC in the phase II PICCOLO trial. MIRV was efficacious in ORR (primary …